Quince Therapeutics, headquartered in South San Francisco, focuses on developing EryDex for Ataxia-Telangiectasia using their AIDE technology for optimal drug delivery. Since their IPO on 2019-05-09, they aim to expand the platform’s applications beyond rare diseases.
Charles S Ryan bought 48,387 shares of QNCX on 20 August at $0.65 per share, worth a total of $31K. They now own 122,461 QNCX shares, or a 65% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
